A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/20/2011	US20110256090 Method for Identifying Genes Involved in Trail-Induced Apoptosis and Therapeutic Applications Thereof
10/20/2011	US20110256089 Hydrogel Type Cell Delivery Vehicle for Wound Healing, and Preparation Method Thereof
10/20/2011	US20110256078 Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers
10/20/2011	US20110256073 Formulations for treating and/or preventing Black-Line Stains
10/20/2011	US20110256071 Thiol-containing fragrance and flavor materials
10/20/2011	US20110256064 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
10/20/2011	US20110256063 Mex3c regulation and target to control obesity and diabetes
10/20/2011	US20110253135 Metal coordination complexes of volatile drugs
10/20/2011	US20110253133 Methods and compositions for administration of oxybutynin
10/20/2011	DE102010022367A1 Pharmaceutical composition in form of lubricating agent or gel used for treating and preventing infections and pain associated with catheterization comprises octenidine or its salts and local anesthetic
10/20/2011	DE102010015793A1 Active agent combination, useful in preparation, preferably cosmetic or dermatological preparation to treat dermatoses, comprises magnolia bark extract containing magnolol and/or honokiol, and surface- or interface-active phosphoric esters
10/20/2011	DE102010015792A1 Wirkstoffkombinationen aus Magnolienrindenextrakt und oberflächenaktiven Agentien Active compound combinations of Magnolia Bark Extract and surface active agents
10/20/2011	DE102010015350A1 Vaginalapplikator Vaginal
10/20/2011	DE102010015242A1 Kombination aus Vitamin K und Nikotinamid Combination of vitamin K and nicotinamide
10/20/2011	DE102010015123A1 New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
10/20/2011	CA2833090A1 Oral pharmaceutical dispersion compositions
10/20/2011	CA2802142A1 Ciprofloxacin dry syrup composition
10/20/2011	CA2800327A1 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
10/20/2011	CA2799550A1 Stabilized statin formulations
10/20/2011	CA2796575A1 Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
10/20/2011	CA2796419A1 Compositions and methods for the prevention and treatment of cancer
10/20/2011	CA2796345A1 Compositions and methods for treating visual disorders
10/20/2011	CA2796336A1 Methods for treating glucose metabolic disorders
10/20/2011	CA2796315A1 Stabilised polyphenol derivatives, process for their manufacture, and uses thereof
10/20/2011	CA2796311A1 Fused derivatives as pi3k.delta. inhibitors
10/20/2011	CA2796280A1 Topical treatments for pain
10/20/2011	CA2796268A1 Methods for treatment of sleep-related breathing disorders
10/20/2011	CA2796253A1 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
10/20/2011	CA2796243A1 Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside
10/20/2011	CA2796207A1 Compound for treatment of respiratory condition or disease
10/20/2011	CA2796205A1 Combination treatment with vegf-c antagonists
10/20/2011	CA2796168A1 Acetaminophen composition
10/20/2011	CA2796150A1 Statins for the prevention or treatment of drug addictions
10/20/2011	CA2796070A1 Androgen induced oxidative stress inhibitors
10/20/2011	CA2796068A1 Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
10/20/2011	CA2796063A1 Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
10/20/2011	CA2796054A1 Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders
10/20/2011	CA2796044A1 Crystalline ingenol mebutate
10/20/2011	CA2796008A1 Inhibitors of protein tyrosine kinase activity
10/20/2011	CA2795952A1 Treatment of cancers having k-ras mutations
10/20/2011	CA2795908A1 Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
10/20/2011	CA2795886A1 Methods and compositions for improving implant osseointegration
10/20/2011	CA2795801A1 Very low-dosed solid oral dosage forms for hrt
10/20/2011	CA2795723A1 Method and ophthalmic composition for treating retinal disease
10/20/2011	CA2795720A1 Pharmaceutical composition for treating macular edema
10/20/2011	CA2795530A1 Amorphous roxithromycin composition
10/20/2011	CA2795408A1 Methods for producing viloxazine salts and novel polymorphs thereof
10/20/2011	CA2795387A1 Novel 3,3-dimethyl tetrahydroquinoline derivatives
10/20/2011	CA2795353A1 Pyrrolobenzodiazepines used to treat proliferative diseases
10/20/2011	CA2795320A1 Method of treating obesity using antioxidant inflammation modulators
10/20/2011	CA2795101A1 Azacyclic spiroderivatives as hsl inhibitors
10/20/2011	CA2795089A1 Combination of organic compounds
10/20/2011	CA2794861A1 Pyrrolopyrazinone inhibitors of kinases
10/20/2011	CA2794859A1 Phthalazin-(2h)-one inhibitors of kinases
10/20/2011	CA2794808A1 Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
10/20/2011	CA2794406A1 Triazole compounds as ksp inhibitors
10/20/2011	CA2793779A1 Organic compound for use in the treatment of liver cancer
10/20/2011	CA2793451A1 Aptamers to .beta.-ngf and their use in treating .beta.-ngf mediated diseases and disorders
10/20/2011	CA2792278A1 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
10/20/2011	CA2790687A1 Aryl - /heteroaryl - cyclohexenyl - tetraazabenzo [e] azulenes as vasopressin antagonists
10/20/2011	CA2786216A1 Arylethynyl derivatives
10/19/2011	EP2377939A2 Transgenic plant-based methods for plant pests using RNAi
10/19/2011	EP2377934A1 Pharmaceutical composition for treatment of cancer and asthma
10/19/2011	EP2377926A1 Chondrocyte-like cell, and method for producing same
10/19/2011	EP2377875A1 Antioxidant
10/19/2011	EP2377874A1 Antioxidant
10/19/2011	EP2377873A1 RNAi modulation of ApoB and uses thereof
10/19/2011	EP2377871A1 1-(2h)-isoquinolone derivative
10/19/2011	EP2377865A1 Cyclobutyl purine derivative, angiogenesis promoting agent, lumenization promoting agent, neurocyte growth promoting agent, and drug
10/19/2011	EP2377864A1 Piperidine GPCR agonists
10/19/2011	EP2377863A1 Piperidine GPCR agonists
10/19/2011	EP2377860A1 Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
10/19/2011	EP2377856A1 Urea glucokinase activators
10/19/2011	EP2377855A1 A valsartanamide dinitrate derivative for the treatment of vascular and metabolic diseases
10/19/2011	EP2377854A1 N-phenyl-dioxo-hydropyrimidines useful as hepatitis C virus (HCV) inhibitors
10/19/2011	EP2377853A1 7,11-Methanocycloocta[b]quinoline derivative as highly functionalizable acetylcholinesterase inhibitors
10/19/2011	EP2377852A1 Labelled huprine derivatives and their use in medical imaging
10/19/2011	EP2377851A1 Isoquinoline derivative
10/19/2011	EP2377850A1 TRPV1 vanilloid receptor antagonists with a bicyclic portion
10/19/2011	EP2377849A2 Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
10/19/2011	EP2377578A1 Stable aqueous compositions comprising amide-protected bioactive creatine species and uses thereof
10/19/2011	EP2377577A1 A benzyl alcohol mixture for treating premature ejaculation
10/19/2011	EP2377558A2 Composition for improving inflammatory disease using abh antigens
10/19/2011	EP2377557A2 Compositions comprising azelastine and methods of use thereof
10/19/2011	EP2377556A1 A compound
10/19/2011	EP2377543A2 Ophthalmic, pharmaceutical and other healthcare preparations with naturally ocurring plant compounds, extracts and derivatives
10/19/2011	EP2377541A1 Use of chitosans to increase nail growth rate
10/19/2011	EP2377540A1 Transdermal patch containing 17-deacetyl norgestimate
10/19/2011	EP2377539A1 Quinazoline analogs as receptor tyrosine kinase inhibitors
10/19/2011	EP2377538A1 Aqueous oral preparation of stable amlodipine
10/19/2011	EP2377537A1 Pirfenidone therapy and inducers of cytochrome P450
10/19/2011	EP2377536A1 Methods of Using Sustained Release Aminopyridine Compositions
10/19/2011	EP2377535A1 Method and composition for treating multiple sclerosis (variants)
10/19/2011	EP2377534A1 Methods of treating alpha adrenergic mediated conditions
10/19/2011	EP2377533A2 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
10/19/2011	EP2377532A1 Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists for treating dermatological disorders
10/19/2011	EP2377531A2 Neurogenesis by modulating angiotensin
10/19/2011	EP2377530A2 Modulation of neurogenesis by PDE inhibition
10/19/2011	EP2377529A1 Use of racemates of pinocembrin in preparing medicaments for treating stroke
10/19/2011	EP2377528A2 Fatty acid metabolism inhibitors for use in the treatment of cancer

1 ... 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 ... 7860